Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Head And Neck Squamous Cell Carcinoma
Explore 249 assets in Head And Neck Squamous Cell Carcinoma →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
OncoNano Medicine, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06022029CT.gov A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | — | Recruiting | — | — | — |
NCT05094804CT.gov A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | — | Unknown | — | — | — |
NCT04305795CT.gov An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04465487CT.gov Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | — | Terminated | — | — | — |
NCT04291105CT.gov Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | — | Recruiting | — | — | — |
NCT03916627CT.gov Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | — | Active Not Recruiting | — | — | — |
NCT03684785CT.gov Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer (this asset) | OncoNano Medicine, Inc. | P2 | CCC · 54 |
| Cis-Diamminedichloroplatinum Ii | Akeso | P3 | BB |
| Carboplatin | Akeso | P4 | BB |
| Irinotecan | Neonc Technologies, Inc. | P2 | BB |
| Capecitabine | Merck Sharp & Dohme LLC | P2 | BB |
| Tisotumab Vedotin | Seagen, a wholly owned subsidiary of Pfizer | P2 | BB |
| Fluorouracilum | Akeso | P2 | BB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Pembrolizumab | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
+42 more in the Head And Neck Squamous Cell Carcinoma cohort
Other indications for Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Skin Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Lung Cancer | — | P2/3 | BB · 65 |
| Nonpapillary Renal Cell Carcinoma | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer in Head And Neck Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-programmed-cell-death-protein-1-human-monoclonal-regn2810-heavy-chain-disulfide-with-human-monoclonal-regn2810-kappa-chain-dimer-head-and-neck-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →